多发性骨髓瘤双特异性抗体的两面：试验前景与现实世界的实践。

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-09-17 DOI:10.1158/2643-3230.BCD-25-0292

Sonja Zweegman, Febe Smits, Niels W C J van de Donk

{"title":"多发性骨髓瘤双特异性抗体的两面：试验前景与现实世界的实践。","authors":"Sonja Zweegman, Febe Smits, Niels W C J van de Donk","doi":"10.1158/2643-3230.BCD-25-0292","DOIUrl":null,"url":null,"abstract":"The real-world effectiveness of the bispecific antibody (BsAb) teclistamab appears to be lower than the efficacy observed in pivotal registration trials. Understanding the drivers of this effectiveness - efficacy gap is essential for guiding the rational selection of patients most likely to benefit, optimizing BsAb therapy in high-risk populations, and ultimately advancing more personalized treatment strategies while supporting sustainable models of care.","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice.\",\"authors\":\"Sonja Zweegman, Febe Smits, Niels W C J van de Donk\",\"doi\":\"10.1158/2643-3230.BCD-25-0292\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The real-world effectiveness of the bispecific antibody (BsAb) teclistamab appears to be lower than the efficacy observed in pivotal registration trials. Understanding the drivers of this effectiveness - efficacy gap is essential for guiding the rational selection of patients most likely to benefit, optimizing BsAb therapy in high-risk populations, and ultimately advancing more personalized treatment strategies while supporting sustainable models of care.\",\"PeriodicalId\":29944,\"journal\":{\"name\":\"Blood Cancer Discovery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":11.5000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2643-3230.BCD-25-0292\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2643-3230.BCD-25-0292","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

双特异性抗体（BsAb） teclistamab的实际有效性似乎低于关键注册试验中观察到的有效性。了解这种有效性-疗效差距的驱动因素对于指导最有可能受益的患者的合理选择，优化高危人群的BsAb治疗，并最终推进更个性化的治疗策略，同时支持可持续的护理模式至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice.

The real-world effectiveness of the bispecific antibody (BsAb) teclistamab appears to be lower than the efficacy observed in pivotal registration trials. Understanding the drivers of this effectiveness - efficacy gap is essential for guiding the rational selection of patients most likely to benefit, optimizing BsAb therapy in high-risk populations, and ultimately advancing more personalized treatment strategies while supporting sustainable models of care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.